IL17A and rheumatoid arthritis: Current treatment of RA inflammation falls into two main categories: nonsteroidal anti-inflammatory drugs (NSAIDs) and cytokine receptor inhibitors, such as Tocilizumab (anti-IL-6 receptor) [10] and Amgen (anti-IL-17) [11].